The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Etanercept Treatment in Children With New-Onset Type 1 Diabetes
Open accessAbstract
OBJECTIVE: To gather preliminary data on the feasibility and efficacy of etanercept therapy to prolong endogenous insulin production in pediatric patients with newly diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS: This was a 24-week double-blind, randomized, placebo-controlled study conducted at the Diabetes Center, Women and Children's Hospital of Buffalo. Eighteen subjects (11 male and 7 female, aged 7.8–18.2 years) were randomly assigned to receive either placebo or etanercept. Inclusion criteria included age 3–18 years, GAD-65 and/or islet cell antibody positivity, A1C >6%, three insulin injections per day, white blood cell count 3,000–10,000, platelets >100,000, and normal liver and renal function. Intention-to-treat analysis was used. RESULTS: A1C at week 24 was lower in the etanercept group (5.91 ± 0.5%) compared with that in the placebo group (6.98 ± 1.2%; P < 0.05) with a higher percent decrease from baseline than in the placebo group (etanercept 0.41 ± 0.1 vs. placebo 0.18 ± 0.21; P < 0.01). The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P < 0.05). From baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23% increase in the placebo group (P < 0.05). Seventeen patients completed the study, and none withdrew because of adverse events. CONCLUSIONS: In this small pilot study, treatment of pediatric patients newly diagnosed with type 1 diabetes with etanercept resulted in lower A1C and increased endogenous insulin production, suggesting preservation of β-cell function. A larger study is needed to further explore safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Pharmaceutical Statistics: Practical and Clinical Applications.
Wallenstein, S., & Bolton, S. (1986) · Journal of the American Statistical Association · doi:10.2307/2289267 · Cited by 430
National Diabetes Fact Sheet, 2011
(2011) · PsycEXTRA Dataset · doi:10.1037/e609522012-001 · Cited by 328
Mandrup-Poulsen, T., Bendtzen, K., Dinarello, C. A., & Nerup, J. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4077 · Cited by 304
Pukel, C., Baquerizo, H., & Rabinovitch, A. (1988) · Diabetes · doi:10.2337/diab.37.1.133 · Cited by 290
IFN- gamma and tumor necrosis factor- alpha . Cytotoxicity to murine islets of Langerhans.
Campbell, I. L., Iscaro, A., & Harrison, L. C. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.7.2325 · Cited by 233
Lechleitner, M., Koch, T., Herold, M., Dzien, A., & Hoppichler, F. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00705.x · Cited by 179
Sabbah, E., Savola, K., Kulmala, P., Veijola, R., Vähäsalo, P., Karjalainen, J., Åkerblom, H. K., & Knip, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.5.5669 · Cited by 143
Yazdani‐Biuki, B., Stelzl, H., Brezinschek, H. P., Hermann, J., Mueller, T., Krippl, P., Graninger, W. B., & Wascher, T. C. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01390.x · Cited by 133
Cited by
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
A guiding map for inflammation
Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Metadata
- Authors
- Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., & Quattrin, T.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-04-14
- Volume
- 32
- Issue
- 7
- Pages
- 1244-1249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138589314
- Cited by
- 280
- References
- 20
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etanercept Treatment in Children With New-Onset Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc09-0054
- The paper
- Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., & Quattrin, T. (2009). Etanercept Treatment in Children With New-Onset Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc09-0054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.